BusinessLegalPipelineResearchEventsProducts
Browse All Stories »
FEATURED
Harrow purchases US commercialization rights to Samsung Bioepis' biosimilar portfolio

Harrow purchases US commercialization rights to Samsung Bioepis' biosimilar portfolio

Acquisition includes two major anti-VEGF therapies for retinal diseases: OPUVIZ and BYOOVIZ, generic equivalents to EYLEA and Lucentis, respectively.

Earn FREE CE 24/7 with Courses by Eyes On Eyecare

Check it out

Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.

TRENDING
Videos
CSI Dry Eye Software releases update for AI-based clinical platform
CSI Dry Eye Software releases update for AI-based clinical platform
Ophthalmology Tech Forum to highlight latest trends and advancements
Ophthalmology Tech Forum to highlight latest trends and advancements
Scope Health brings eyelid health to forefront with new PF OPTASE LIFE eye cream
Scope Health brings eyelid health to forefront with new PF OPTASE LIFE eye cream
Patient studies show iVIZIA lubricant eye drops provide relief for all forms of dry eye
Patient studies show iVIZIA lubricant eye drops provide relief for all forms of dry eye
Watch More
Business
Harrow purchases US commercialization rights to Samsung Bioepis' biosimilar portfolio
Harrow purchases US commercialization rights to Samsung Bioepis' biosimilar portfolio
Meta reportedly buys minority stake in EssilorLuxottica
Meta reportedly buys minority stake in EssilorLuxottica
Leadership watch: ViaLase, J&J, Alcon, and myze make executive additions
Leadership watch: ViaLase, J&J, Alcon, and myze make executive additions
4DMT cuts 25% of workforce and fast-tracks wet AMD gene therapy program
4DMT cuts 25% of workforce and fast-tracks wet AMD gene therapy program
Research
Researchers develop infrared light-sensing contacts for humans
Researchers develop infrared light-sensing contacts for humans
Pivotal study validates SCANLY Home OCT device for nAMD management
Pivotal study validates SCANLY Home OCT device for nAMD management
New IRD genetic testing maps mutations to improve diagnoses
New IRD genetic testing maps mutations to improve diagnoses
Surprising protective role of estrogen may lower glaucoma risk in women
Surprising protective role of estrogen may lower glaucoma risk in women
Pipeline
FDA accepts Aldeyra's resubmitted reproxalap NDA
FDA accepts Aldeyra's resubmitted reproxalap NDA
Belite Bio concludes enrollment for phase 3 GA trial on oral tinlarebant
Belite Bio concludes enrollment for phase 3 GA trial on oral tinlarebant
FDA OKs AAVantgarde's IND for Stargardt gene therapy trial
FDA OKs AAVantgarde's IND for Stargardt gene therapy trial
Nanoscope begins rolling BLA submission for RP gene-agnostic therapy
Nanoscope begins rolling BLA submission for RP gene-agnostic therapy
Products
Lupin launches Lotemax generic suspension in the US
Lupin launches Lotemax generic suspension in the US
Regener-Eyes ends recall of remaining older product inventory
Regener-Eyes ends recall of remaining older product inventory
J&J launches Acuvue Oasys Max 1-Day MF contact lens for astigmatism
J&J launches Acuvue Oasys Max 1-Day MF contact lens for astigmatism
CSI Dry Eye Software releases update for AI-based clinical platform
CSI Dry Eye Software releases update for AI-based clinical platform
Legal
FDA scrutiny of unapproved CXL trials reveals critical lapses in patient safety and regulatory adherence
FDA scrutiny of unapproved CXL trials reveals critical lapses in patient safety and regulatory adherence
West Virginia OD bill to permit use of ophthalmic lasers
West Virginia OD bill to permit use of ophthalmic lasers
Montana passes OD scope expansion for laser procedures
Montana passes OD scope expansion for laser procedures
West Virginia bill to change newborn blindness prevention law
West Virginia bill to change newborn blindness prevention law
Archives
Hello 2023 — Weekly Glance
Hello 2023 — Weekly Glance
Can we treat uveitis without steroids? — Weekly Glance
Can we treat uveitis without steroids? — Weekly Glance
Can I have one dilation drop instead of two? — Weekly Glance
Can I have one dilation drop instead of two? — Weekly Glance
Are those dilation reversal drops available yet? — Weekly Glance
Are those dilation reversal drops available yet? — Weekly Glance
Events
Octane's Ophthalmology Tech Forum highlights AI and personalized medicine
Octane's Ophthalmology Tech Forum highlights AI and personalized medicine
Optometry Divas to host celebratory 10-year anniversary events
Optometry Divas to host celebratory 10-year anniversary events
Eyes On Glaucoma 2025 highlights advancements in disease care
Eyes On Glaucoma 2025 highlights advancements in disease care
Vision Expo shifting to single annual event in 2026
Vision Expo shifting to single annual event in 2026
Browse All Stories »